Patents by Inventor Scott Pegan

Scott Pegan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered organophosphorus acid anhydrolases and methods of use thereof
    Patent number: 10260054
    Abstract: Genetically engineered organophosphorus acid anhydrolases (OPAA) with improved catalytic efficiency and relaxed stereospecificity are provided. The variants typically include a mutation at the residue corresponding to H343 of wildtype Alteromonas sp. OPAA. The mutation allows the OPAA enzyme to effectively process both VR enantiomers. The OPAA optionally include one or more mutations selected the residues corresponding to Y212, V342, and I215 of wildtype Alteromonas sp. OPAA which improve the enzyme's catalytic efficiency for VX and VR. A particularly preferred OPAA includes mutations at the residues corresponding Y212F, V342L, I215Y, and H343D relative to wildtype Alteromonas sp. OPAA. Compositions including an effective amount of OPAA to increase hydrolysis of an organophosphate, and methods of use thereof for treating subjects exposed to an organophosphate, or a surface or liquid contaminated with an organophosphate are also provided.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: April 16, 2019
    Assignees: University of Georgia Research Foundation, Inc., The United States of America, as represented by the Secretary of the Army
    Inventors: Scott Pegan, Steven P. Harvey
  • ENGINEERED ORGANOPHOSPHORUS ACID ANHYDROLASES AND METHODS OF USE THEREOF
    Publication number: 20160355792
    Abstract: Genetically engineered organophosphorus acid anhydrolases (OPAA) with improved catalytic efficiency and relaxed stereospecificity are provided. The variants typically include a mutation at the residue corresponding to H343 of wildtype Alteromonas sp. OPAA. The mutation allows the OPAA enzyme to effectively process both VR enantiomers. The OPAA optionally include one or more mutations selected the residues corresponding to Y212, V342, and I215 of wildtype Alteromonas sp. OPAA which improve the enzyme's catalytic efficiency for VX and VR. A particularly preferred OPAA includes mutations at the residues corresponding Y212F, V342L, I215Y, and H343D relative to wildtype Alteromonas sp. OPAA. Compositions including an effective amount of OPAA to increase hydrolysis of an organophosphate, and methods of use thereof for treating subjects exposed to an organophosphate, or a surface or liquid contaminated with an organophosphate are also provided.
    Type: Application
    Filed: June 6, 2016
    Publication date: December 8, 2016
    Inventors: Scott Pegan, Steven P. Harvey